PMC Board Continues to Cultivate Leadership from Across Health Care System
News Jun 06, 2015
Continuing to convene leaders in personalized medicine from across the health care system, the Personalized Medicine Coalition (PMC) has announced the election of two representatives from both the diagnostic and pharmaceutical industries to its Board of Directors: Genomic Health Chairman of the Board, CEO and President, Kim Popovits and Pfizer Executive Director and Head of Diagnostics, Hakan Sakul, Ph.D.
“The additional representation from the diagnostic and pharmaceutical communities further strengthens PMC’s ability to engage all of the stakeholders in health care so that they can work together to develop consensus solutions to the challenges facing the field,” said PMC President Edward Abrahams, Ph.D. “The future of personalized medicine depends on collaboration among multiple sectors.”
In her role at Genomic Health, Popovits leads the company’s efforts to revolutionize the treatment of cancer care through genomic tests for breast, colon and prostate cancers, as well as a pipeline of liquid biopsy tests.
“PMC has been at the forefront of advocating on behalf of innovators, researchers, patients and physicians, and I am delighted to join the Board to help lead the national discussion around advancing the adoption of personalized medicine through public policy,” she said.
Sakul leads Pfizer’s efforts in companion diagnostics across Pfizer’s pharmaceutical pipeline. His work has resulted in several companion diagnostic partnerships, including the initiative that led to the simultaneous FDA approvals of Xalkori (crizotinib) and its companion diagnostic in 2011.
“As a founding member, Pfizer has been active in PMC for more than 10 years,” Sakul said. “As a new Board member, I am delighted to work closer with the PMC staff and my fellow PMC Board members to help advance personalized medicine.”
The appointments coincide with the expiring terms of Felix Frueh, Ph.D., Human Longevity and Jeffrey Cossman, M.D., formerly of United States Diagnostic Standards.
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE